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Abstract
A discrepancy between oxygen availability and demand has been found in most chronic kidney diseases (CKD)
irrespective of etiology. This results from a combination of structural and functional changes that are commonly
associated with the development of fibrosis, which include a reduction in peritubular blood flow, luminal
narrowing of atherosclerotic vessels, capillary rarefaction and vascular constriction due to altered expression of
vasoactive factors and signaling molecules (e.g. angiotensin II, endothelin, nitric oxide). Consistent with decreased
renal oxygenation in CKD is the increased expression of the oxygen-sensitive a-subunit of hypoxia-inducible factor
(HIF)-1. HIF transcription factors are members of the Per-ARNT-Sim (PAS) family of heterodimeric basic helix-loop-
helix transcription factors and consist of an oxygen-sensitive a-subunit and a constitutively expressed b-unit, also
known as the aryl-hydrocarbon-receptor nuclear translocator (ARNT) or HIF-b. Recent experimental evidence
suggests that prolonged activation of HIF signaling in renal epithelial cells enhances maladaptive responses, which
lead to fibrosis and further tissue destruction. Cell type-specific functions of individual HIF transcription factors and
their relevant transcriptional targets are discussed in the context of renal fibrogenesis.
Introduction
Despite the very large blood flow (~20% of total cardiac
output), the kidneys, which carry out complex and energy
consuming cellular transport functions, operate under
markedly reduced oxygen tension, with regional oxygen
levels ranging from 10 to 60 mmHg. A reduction in renal
oxygenation occurs in most chronic kidney diseases
(CKD) irrespective of etiology. This is due to a combina-
tion of several pathophysiological and morphologic
changes, which are typically associated with chronic kid-
ney injury. These include increased oxygen demand from
hyperfiltration and tubular hypertrophy, capillary rarefac-
tion, glomerular injury, luminal narrowing of atherosclero-
tic vessels, as well as vascular constriction due to altered
expression of vasoactive factors and signaling molecules
(e.g. angiotensin II, endothelin, nitric oxide). The resulting
reduction in renal oxygen availability is furthermore exa-
cerbated by extra-cellular matrix (ECM) expansion, which
limits oxygen diffusion, and by renal anemia [1,2]. Blood
oxygen level-dependent (BOLD) MRI, molecular and his-
tological techniques, as well as measurements of renal oxy-
gen levels with microelectrodes have been used to assess
tissue oxygenation in chronic kidney diseases, including
diabetic and IgA nephropathy, obstructive nephropathy,
fibrosis associated with 5/6 nephrectomy and anti-Thy1
glomerulonephritis (for an overview of these studies see
[1-4]).
Consistent with decreased renal oxygenation in CKD is
the increased expression of the oxygen-sensitive a-subunit
of hypoxia-inducible factor (HIF)-1 in renal biopsy mate-
rial from patients with CKD [5,6]. The heterodimeric basic
helix-loop-helix transcription factors HIF-1 and HIF-2 are
key mediators of cellular adaptation to hypoxia, and
belong to the PAS {PER/aryl-hydrocarbon-receptor
nuclear translocator (ARNT)/single minded (SIM)} family
of transcription factors. They consist of an oxygen-sensi-
tive a-subunit and a constitutively expressed b-subunit,
which is also known as the aryl hydrocarbon receptor
nuclear translocator (ARNT), and facilitate both oxygen
delivery and cell survival by stimulating erythropoiesis,
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HIF-2 are furthermore involved in the regulation of biolo-
gical processes that are relevant to wound healing, tissue
repair and fibrogenesis, such as extracellular matrix synth-
esis and turnover, cell adhesion and migration, and epithe-
lial to mesenchymal transition (EMT) [7-12].
HIF heterodimers activate gene transcription in response
to hypoxia by binding to specific DNA sequences, which
are known as hypoxia-response elements (HREs) and by
recruiting transcriptional co-activators such as CBP/p300
(Figure 1). While HIF-a is continuously synthesized, it is
rapidly degraded under normoxia, keeping HIF signaling
at minimal levels when oxygen tension is in normal range.
HIF degradation under normoxia requires hydroxylation
of specific proline residues within the oxygen-dependent
degradation domain of HIF-a, enabling interaction with
the von Hippel-Lindau tumor suppressor pVHL, which
functions as the substrate recognition component of an E3
ubiquitin ligase complex [13,14]. HIF hydroxylation
depends on the presence of molecular oxygen, ferrous
iron and ascorbate, and is carried out by 2-oxoglutarate-
dependent dioxygenases (prolyl-4-hydroxylase domain
(PHD) proteins). Three major HIF-hydroxylating enzymes
have been identified, PHD1, 2 and 3, of which PHD2 is
most important for normoxic HIF degradation [14]. A sec-
ond hypoxic switch operates in the carboxy-terminal
transactivation domain of HIF-a with the hydroxylation of
an asparagine residue. Under hypoxic conditions aspara-
gine hydroxylation is inhibited and CBP/p300 recruitment
facilitated, enabling increased levels of transcription [14].
While HIF has been shown to be cytoprotective in acute
kidney injury [3], work by our laboratory and others now
suggests that prolonged activation of HIF signaling in
renal epithelial cells enhances maladaptive responses,
which lead to fibrosis and tissue destruction. Specifically,
our laboratory has identified epithelial HIF-1a as a promo-
ter of kidney fibrosis, and has demonstrated that HIF-1
activation stimulates collagen accumulation and inflamma-
tory cell recruitment in experimental models of CKD
[5,15].
Results
Evidence of HIF activation in renal biopsy material from
patients with CKD
A discrepancy between oxygen availability and demand
has been demonstrated in experimental CKD. In order to
investigate the expression levels of HIF-1a in tissues from
patients with CKD, we have used immunohistochemistry
to analyze archival, paraffin-embedded renal biopsy mate-
rial from patients with different stages of diabetic nephro-
pathy, which is the leading cause of end stage renal
disease. We found a statistically significant correlation of
disease stage with the percentage of HIF-1a-expressing
tubular epithelial cells, which suggested that the level of
hypoxia in diabetic CKD associates with disease severity,
extent of fibrosis and disease progression (Figure 2) [5].
HIF-1a was also detected in fibrotic areas of renal tissues
from patients with IgA nephropathy [5]. Genome-wide
gene expression analysis of micro-dissected renal biopsy
material from patients with diabetic nephropathy (tubu-
lointerstitium only) revealed that approximately 50 of
1349 differentially regulatedg e n e sw e r ee s t a b l i s h e do r
putative HIF transcriptional targets [5]. Increased expres-
sion was found for phosphoglycerate kinase-1 (PGK-1),
chemokine receptor CXCR4, lysyl oxidase-like 2 (LOXL2)
and phosphofructokinase (PFKFB3). A comparable increase
in LOXL2 expression was also seen by real-time PCR in
micro-dissected tubulointerstitium from patients with IgA
nephropathy and hypertensive nephrosclerosis (Figure 3),
suggesting a general association between LOXL2 expres-
sion and the presence of CKD [5]. Taken together with
studies in experimental animal models, our clinical
Figure 1 Overview of PHD/HIF signaling. Under normoxia, both
HIF-1a and HIF-2a are hydroxylated by prolyl-4-hydroxylases and
are targeted for proteasomal degradation by the von Hippel-Lindau
(pVHL)-E3 ubiquitin ligase complex (shown are key components of
this complex). Binding to prolyl-hydroxylated HIF-a occurs at the b-
domain of pVHL, which spans amino acid residues 64 - 154. The C-
terminal a-domain links the substrate recognition component pVHL
to the E3 ubiquitin ligase via elongin C. When prolyl-4-hydroxylation
is inhibited (e.g. by hypoxia, ROS), HIF-a subunits are stabilized and
translocate to the nucleus where they heterodimerize with ARNT.
HIF-a/ARNT heterodimers bind to the HIF consensus-binding site,
RCGTG, resulting in increased expression of target genes. Factor-
inhibiting-HIF (FIH) is a dioxygenase that modulates transcriptional
cofactor recruitment (CBP/p300) via asparagine (Asn) hydroxylation
of the HIF-a carboxy-terminal transactivation domain. In addition to
ROS, nitric oxide, Krebs cycle metabolites succinate and fumarate,
cobalt chloride and iron chelators such as desferrioxamine inhibit
HIF prolyl-4-hydroxylases in the presence of oxygen. Abb.: CoCl2,
cobalt chloride; Fe
2+, ferrous iron; NO, nitric oxide; PHI, prolyl-4-
hydroxylase inhibitors (structural 2-oxoglutarate analogs); ROS,
reactive oxygen species; ub, ubiquitin.
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system associates with the development and progression
of renal fibrosis.
HIF promotes EMT in primary renal epithelial cells
Recent findings by our laboratory and other groups sug-
gest that hypoxia, via activation of HIF-1 signaling,
enhances fibrogenesis through HRE-mediated upregula-
tion of extracellular matrix (ECM) modulators, such con-
nective tissue growth factor (CTGF), tissue inhibitor of
matrix metalloproteinase (TIMP)-1 and plasminogen
activator inhibitor (PAI)-1 [16-18]. PAI-1, for example, is
known to enhance fibrosis when overexpressed in trans-
genic mice, whereas PAI-1 deficiency is protective
[19,20].
An important cellular process, which is associated with
the development of tubulointerstitial fibrosis, is EMT
[21-23]. EMT in the setting of CKD is considered a dis-
ease-promoting process by which epithelial cells acquire
a mesenchymal phenotype and then migrate into the
interstitial compartment through breaks in the basement
membrane, where they together with resident cells pro-
duce extracellular matrix as myofibroblasts [24]. To
explore whether EMT in renal tubular epithelial cells is
modulated by hypoxia via HIF, we isolated primary tubu-
lar epithelial cells (PTECs) from the kidney cortex of
genetically modified mice, which express a tetracycline-
inducible Cre-recombinase permitting inactivation of
HIF-1a in vitro. Using this approach, we demonstrated
that hypoxia (1% O2) led to morphologic and gene
expression changes that were consistent with EMT, and
furthermore enhanced the migratory ability of PTECs in
a HIF-1-dependent fashion. Since HIF-regulation of lysyl
oxidase (LOX) was required for hypoxia-induced migra-
tion of breast cancer cells [25], we investigated whether
lysyl oxidases were involved in mediating the EMT-pro-
moting effects of hypoxia in PTECs. We first established
that the hypoxic regulation of LOX and its homologue
LOXL2 was HIF-1-dependent, and then used pharmaco-
logical means to investigate the effects of lysyl oxidase
inhibition on epithelial cell migration. Lysyl oxidase inhi-
bitors b-aminoproprionitrile (BAPN) or bathocuproine
Figure 2 HIF-1a expression in diabetic nephropathy. HIF-1a immunostaining in formalin-fixed, paraffin-embedded renal biopsy tissues from
patients with diabetic nephropathy (DN). (A) Shown are non-affected control kidney tissue (nl. +, less than 25% of tubular epithelial cells are
stained) and kidney tissue from a patient with severe DN (DN +++, positive staining is detected in >50% of tubular epithelial cells). Arrows
highlight cells with nuclear HIF-1a staining. (B) Summary of HIF-1a expression analysis in DN. DN cases are grouped according to
tubulointerstitial injury score as previously described [53]. The number of biopsies with glomerular (gl) or tubular staining (t) is shown in brackets.
-, absence of staining; +: 1-25% of cells per visual field with staining; ++: >25-50% and +++: >50% of cells with positive staining.
Figure 3 Increased expression of LOXL2 in CKD.R e a lt i m eP C R
analysis of LOXL2 expression in micro-dissected tubulointerstitium
from patients with DN, IgA nephropathy (IgAN) and hypertensive
nephrosclerosis (NS). Shown are relative expression values normalized
to 18S. Pre-transplant biopsies from living related donor kidneys (LD)
were used as control. ** P < 0.001 by Mann-Whitney test.
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vation, and attenuated hypoxia-enhanced migration in a
scratch wound closure assay; complete closure was
observed by 24 hours in hypoxic cells, whereas pre-treat-
ment with either BAPN or BCS inhibited migration with
the scratch not closing for at least 30 hours (Figure 4).
Lysyl oxidases are copper-dependent enzymes with intra-
cellular and extracellular activities, and catalyze the oxi-
dation of lysine residues in collagen and elastin fibers,
thereby modulating cell migration and epithelial differen-
tiation [26,27]. BAPN is an irreversible inhibitor of lysyl
oxidases and inhibits all lysyl oxidase family members.
Taken together, our data suggested that hypoxia
induces morphologic and molecular changes that are
consistent with EMT. Although some changes did not
involve HIF-1, e.g. increased expression of a-smooth
muscle actin (SMA), augmentation of epithelial migra-
tion in hypoxia involved HIF-1-mediated induction of
lysyl oxidases.
Inactivation of epithelial HIF-1 improves renal fibrosis in
vivo
To investigate the contribution of epithelial HIF-1 signal-
ing to the development of kidney fibrosis in vivo, we used
a model of renal fibrogenesis that is based on unilateral
ureteral obstruction (UUO). In this model one of the
ureters is ligated, blocking urine flow completely, which
results in rapidly progressing fibrosis in the affected kid-
ney. UUO kidneys develop hypoxia, as demonstrated by
pimonidazole staining and epithelial HIF-1a stabilization.
HIF-2a was detected in tubulointerstitial cells, which is
consistent with immunohistochemical studies in hypoxic
kidneys [3,5].
To assess the contribution of epithelial HIF-1 to fibrosis
in this model, we compared wild type mice to animals that
were HIF-1-defcient in the proximal renal tubule. Proxi-
mal tubule-restricted inactivation of HIF-1 was accom-
plished through use of a Cre-recombinase under the
control of the phosphoenolpyruvate carboxykinase
(PEPCK) promoter. Inactivation of HIF-1 in proximal
tubule epithelial cells resulted in reduced accumulation of
collagen, reduced macrophage accumulation and reduced
expression of FSP-1-positive cells following UUO [5], sup-
porting our in vitro findings and the notion that HIF-1
functions as a profibrotic transcription factor under
chronic injury conditions.
Increased expression of epithelial HIF promotes fibrosis in
vivo
Since genetic inactivation of HIF-1a in the context of
UUO resulted in attenuation of fibrosis and inflammation,
we next investigated whether activation of epithelial HIF
in a normoxic context could enhance fibrogenesis in vivo.
For these studies we used Cre-recombinase transgenes
that either were driven by the gamma-glutamyl transpepti-
dase (g-GT) promoter or were tetracycline-inducible
under the control of a Pax8-driven transactivator [28].
Inhibition of HIF-a degradation as a result of pVHL inac-
tivation produced inflammation and rapid extracellular
matrix deposition in the medulla (Liu, Kobayashi, Farsijani
and Haase, unpublished data). HIF activation in the proxi-
mal tubule accelerated fibrosis in a CKD model based on
5/6 nephrectomy, and resulted in spontaneous fibrosis
development in older mice [15]. Pharmacologic inhibition
o fH I F - 1w i t hY C - 1c o m p o u n d[ 3 - ( 5 ’-hydroxymethyl-2’-
furyl)-1-benzylindazole] abrogated these effects and slo-
wed the development of fibrosis in mice subjected to
UUO [15], suggesting that HIF-1 may represent a novel
pharmacologic target to slow the progression of CKD.
Discussion
Renal epithelial cells contribute to the development of
kidney fibrosis, as they increase and remodel ECM when
stimulated with TGF-b1, angiotensin II and other cyto-
kines [29,30], or when they transition into myofibroblasts
as a result of EMT [23,24]. Increased HIF expression has
been found in animal models of CKD and in renal biopsy
material from patients with diabetic nephropathy and
other forms of renal disease, where it correlates with dis-
ease severity [5,31,32]. Our laboratory has identified
epithelial HIF-1 as a promoter of renal fibrosis in experi-
mental UUO [5]. The biological outcome of activated
HIF signaling, however, is different under conditions of
Figure 4 LOX inhibition impairs migration of primary renal
epithelial cells in vitro. Cells were cultured under hypoxia for 6
days, 2 h prior to placing a scratch wound, lysyl oxidase inhibitors
BAPN or BCS were added and cell migration monitored over 30 h.
Hx: Control cells (hypoxia without inhibitor). Magnification ×100.
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nucleus of renal tubular epithelial cells, where it
dimerizes with HIF-1b to form transcriptionally active
HIF-1. Whereas HIF-1a is expressed in renal epithelial
and endothelial cells, HIF-2a is expressed in erythropoie-
tin (EPO)-producing renal interstitial fibroblasts,
endothelial and glomerular cells [3]. Genetic studies in
mice have demonstrated that reduced expression of
either HIF-1a or HIF-2a worsens clinical outcome of
acute ischemic kidney injury [33,34]. While the cell types
that contribute to HIF-mediated cytoprotection remain
to be determined, endothelial HIF-2 appears to amelio-
rate renal ischemia reperfusion injury through increased
expression of ROS scavenging enzymes, such as superox-
ide dismutase (SOD) [33].
In the context of chronic renal injury the biological con-
sequences of HIF activation are different, and negatively
impact clinical outcome, that is, promote fibrosis, ulti-
mately leading to the development of end stage renal dis-
ease. This may occur through increased expression of i)
ECM-modifying genes, such as LOX and PAI-1, ii) func-
tional co-operation with transforming growth factor
(TGF)-b1, iii) promotion of epithelial to mesenchymal
transition (EMT), and iv) through modulation of renal
inflammation [35]. Hypoxia induces collagen I,d e c r e a s e s
matrix-metallopeptidase 2 (MMP-2) in renal epithelial
cells [36], and increases PAI-1 [18], tissue-inhibitor of
metalloproteinase-1 (TIMP-1) [36] as well as connective
tissue growth factor (CTGF) [16] through HIF-mediated
transcriptional responses. Synergistic co-operation
between HIF and non-HIF pathways, such as the pro-
fibrotic TGF-b1/SMAD3 signaling pathway, may further
enhance the expression of HIF-regulated genes in the
CKD setting; HIF-1 and TGF-b1 have been shown to co-
regulate vascular endothelial growth factor (VEGF) [37],
endoglin [38] and EPO [39]. The notion of HIF and TGF-
b1 working together in the context of CKD is furthermore
supported by the observation that hypoxia synergizes with
TGF-b1 with regard to the production of certain collagens
[40,41].
While hypoxia is the main stimulus for HIF activation,
signaling molecules with key roles in the pathogenesis of
CKD, such as angiotensin II (Ang II), have also been
shown to activate HIF-1 via prolyl-4-hydroxylase inhibi-
tion. PHD inhibition in this setting results from increased
ROS generation and diminished intracellular ascorbate
levels, leading to the oxidation of a critical iron atom that
is positioned in the center of the PHD catalytic domain
[42]. Although AngII-generated ROS is largely derived
from activation of NADPH oxidase [43], others have sug-
gested that AngII-induced HIF-1a stabilization may be
mediated by mitochondrial ROS [44]. In this context,
recent studies in renal interstitial fibroblasts have proposed
that HIF-1 functions downstream of an Ang II-induced
pro-fibrotic signaling cascade, which stimulates EMT and
the production of collagen [45].
There is growing experimental evidence that hypoxia via
HIF promotes EMT. This occurs through i) modulation of
activity of EMT inducers or their receptors (e.g. TGF-b1;
c-met proto-oncogene [28]), ii) regulation of expression
levels and activity of EMT-associated signaling molecules
and downstream effectors (e.g. Notch and b-catenin
[46,47]), and iii) via regulation of expression and activity
levels of EMT-inducing transcriptional repressors, such as
snail (SNAI1) [48]. In the context of CKD, renal tubular
epithelial cells loose apico-basal polarity, become motile
and acquire a mesenchymal phenotype. It has been pro-
posed that they are able to migrate into the interstitium,
where they together with resident cells would produce
ECM as myofibroblasts [24]. Irrespective of cellular origin,
the accumulation of myofibroblasts closely correlates with
the degree of interstitial damage and the risk of disease
progression. Earlier in vivo studies using genetically tagged
renal epithelial cells have suggested that up to 36% of
interstitial myofibroblasts are EMT-derived, whereas
approximately 15% stem from bone marrow, with the
remainder being of resident fibroblast origin [21]. The
degree to which EMT contributes to the renal myofibro-
blast pool, however, is intensely debated and remains
unclear [49]. More recent studies indicate that pericytes
[50] and/or endothelial cells [51] are major sources of
ECM-producing myofibroblasts.
HIF-1 induction of LOX and LOXL-2 has been shown
to promote migration in primary renal epithelial, and in
breast and cervical cancer cells, which was associated with
decreased E-cadherin expression [5,25]. Although initially
identified by their ability to crosslink collagen and elastin
fibers, LOX and LOXL proteins also carry out intracellular
functions and display a range of biological activities that
extend beyond ECM cross-linkage [26]. In a recent report
Peinado et al. demonstrated that LOXL2 and LOXL3 have
the potential to regulate EMT by stabilizing and promot-
ing the activity of transcriptional repressor SNAI1 [52].
Our finding that HIF activation in epithelial cells pro-
motes renal fibrosis has immediate clinical implications,
as it encourages therapies that aim at improving tissue
oxygenation to retard disease progression. Because HIF
regulates multiple biological processes, which include
erythropoiesis and iron metabolism, its systemic pharma-
cological inhibition is not desirable. Certain HIF regu-
lated proteins, however, may represent better therapeutic
targets to slow progression of CKD. Pharmacological ini-
hibition of lysyl oxidases phenocopied the effects of
genetic HIF-1 inactivation on cell motility and fibrogen-
esis, suggesting that lysyl oxidases are important contri-
butors to the pathogenesis of renal fibrosis. In keeping
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in renal biopsy tissues from patients with CKD under-
scoring its relevance to the pathogenesis of CKD irre-
spective of etiology (Figure 5). Whether pharmacological
inhibition of lysyl oxidases is feasible in clinical practice
to slow progression of CKD certainly warrants further
investigation.
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